Genome Medicine (May 2022)

Rapid whole genome sequencing of critically ill pediatric patients from genetically underrepresented populations

  • Nour Halabi,
  • Sathishkumar Ramaswamy,
  • Maha El Naofal,
  • Alan Taylor,
  • Sawsan Yaslam,
  • Ruchi Jain,
  • Roudha Alfalasi,
  • Shruti Shenbagam,
  • Martin Bitzan,
  • Lemis Yavuz,
  • Hamda Abulhoul,
  • Shiva Shankar,
  • Dalwinder Janjua,
  • Devendrasing Jadhav,
  • Munira Mahmoud Al Maazmi,
  • Walid Abuhammour,
  • Alawi Alsheikh-Ali,
  • Mohamed Al Awadhi,
  • Abdulla Al Khayat,
  • Ahmad N. Abou Tayoun

DOI
https://doi.org/10.1186/s13073-022-01061-7
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 5

Abstract

Read online

Abstract We describe a case series of five infants (age range: 1–90 days; 4 females and 1 male) who presented to Al Jalila Children’s intensive care units (ICU) with complex multisystem disorders. Patients were Emirati, Kenyan, Jordanian, Filipino, or Pakistani. Trio rapid whole genome sequencing (rWGS) was performed on all five patients and their parents within the hospital’s genomics facility. Results were returned within ~37 h from blood sample draws and were diagnostic in 3 out of 5 patients. Positive findings were a homozygous pathogenic variant in POMT1 gene causing muscular dystrophydystroglycanopathy, a mosaic tetrasomy of the short arm of chromosome 12 (12p13.33p11.1) causing Pallister-Killian syndrome, and compound heterozygous pathogenic variants in the LIPA gene causing lysosomal acid lipase deficiency and Wolman disease. The rWGS analysis provided fast and precise diagnostic findings in those 3 patients and also aided in devising better management plans for them in the intensive care setting. For example, the 3-month-old infant with pathogenic variants in the LIPA gene is now a candidate for an FDA-approved, potentially lifesaving enzyme replacement therapy (sebelipase alfa). Our case series emphasize the feasibility and utility of rWGS in pediatric intensive care setting, in a diverse population that has long been underserved in genomic services. Significant investments in local healthcare infrastructure are needed, globally, for more equitable access of genomic medicine among vulnerable patients.